To Home Page of PHI website to PHI's Secure Shopping Cart
PHI's Education
About PHI Education Advocacy Research Networking to How to Donate to Membership Application

Post-Polio Health (ISSN 1066-5331)

Vol. 31, No. 3, Summer 2015


Multicenter, Multi-country Study Underway

Joan L. Headley, Executive Director, PHI

Typical of most studies, the name of the most recently announced study related to post-polio syndrome is long but exactingly descriptive: A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel-Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients with Post-Polio Syndrome.

The main purpose of the study is to select a dose of Flebogamma® 5% DIF and confirm the efficacy of the selected Flebogamma® 5% DIF dose by assessing physical performance, as measured by 2 Minutes Walk Distance (2MWD) test.


Back to contents of this issue ...
Past Issues, Listed by Topic
Past Issues, Listed by Volume and Date


















Back to top